Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants

被引：20
|
作者：
Almeida, Volia De Carvalho [1 ]
Mussi-Pinhata, Marisa Marcia [2 ]
Sandoval De Souza, Cleonice Barbosa [2 ]
Kubo, Christina Arslanian [3 ]
Martinez, Edson Zangiacomi [4 ]
Carneiro-Sampaio, Magda Maria [5 ]
Duarte, Geraldo [6 ]
机构：
[1] Univ Fed Sao Carlos, Biol & Hlth Sci Ctr, Dept Med, BR-13565905 Sao Carlos, SP, Brazil
[2] Univ Sao Paulo, Dept Pediat, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[3] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil
[4] Univ Sao Paulo, Dept Social Med, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
[5] Univ Sao Paulo, Dept Pediat, Fac Med, BR-05403900 Sao Paulo, Brazil
[6] Univ Sao Paulo, Dept Gynecol & Obstet, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
来源：
VACCINE | 2009年 / 27卷 / 29期
基金：
巴西圣保罗研究基金会;
关键词：
Pneumococcal polysaccharide vaccine; HIV-infected pregnant woman; Passively acquired pneumococcal antibodies; MATERNAL IMMUNIZATION; STREPTOCOCCUS-PNEUMONIAE; PLACENTAL-TRANSFER; 22F POLYSACCHARIDE; CONJUGATE VACCINE; VIRAL LOAD; SERUM IGG; DISEASE; ADULTS; TRANSMISSION;
D O I：
10.1016/j.vaccine.2009.04.018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 613, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3856 / 3861
页数：6
相关论文
共 50 条
  • [1] Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies
    Quiambao, Beatriz P.
    Nohynek, Hanna M.
    Kayhty, Helena
    Ollgren, Jukka P.
    Gozum, Lorena S.
    Gepanayao, Connie P.
    Soriano, Victoria C.
    Makela, Pirjo Helena
    VACCINE, 2007, 25 (22) : 4470 - 4477
  • [2] Immunogenicity of A 23-Valent Pneumococcal Polysaccharide Vaccine Among Mexican Children
    Elva Espinosa-Padilla, Sara
    Murata, Chiharu
    Estrada-Parra, Sergio
    Santos-Argumedo, Leopoldo
    Mascarenas, Cesar
    Franco-Paredes, Carlos
    Javier Espinosa-Rosales, Francisco
    ARCHIVES OF MEDICAL RESEARCH, 2012, 43 (05) : 402 - 405
  • [3] Evaluation of effectiveness, safety and cost-benefit of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
    Zou, Xiaobai
    He, Jianmei
    Zheng, Jun
    Liang, Mengran
    Gao, Jinjin
    Huang, Jianwen
    Jiang, Yang
    Jiang, Yonglin
    Chen, Xi
    VACCINE, 2022, 40 (01) : 37 - 42
  • [4] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
    Simonsen, V
    Brandao, AP
    Brandileone, MCC
    Yara, TI
    Di Fabio, JL
    Lopes, MH
    Jacob, W
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2005, 38 (02) : 251 - 260
  • [5] Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects
    Ciprero, Karen
    Zykov, Kirill A.
    Briko, Nikolay I.
    Shekar, Tulin
    Sterling, Tina M.
    Bitieva, Elizaveta
    Stek, Jon E.
    Musey, Luwy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2142 - 2147
  • [6] Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users
    Amendola, A
    Tanzi, E
    Zappa, A
    Colzani, D
    Boschini, A
    Musher, DM
    Zanetti, AR
    VACCINE, 2002, 20 (31-32) : 3720 - 3724
  • [7] Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
    Haggenburg, Sabine
    Garrido, Hannah M. Garcia
    Kant, Iris M. J.
    van der Straaten, Hanneke M.
    De Boer, Fransien
    Kersting, Sabina
    Issa, Djamila
    Te Raa, Doreen
    Visser, Hein P. J.
    Kater, Arnon P.
    Goorhuis, Abraham
    De Heer, Koen
    VACCINES, 2023, 11 (07)
  • [8] Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
    Lombardi, Francesca
    Belmonti, Simone
    Fabbiani, Massimiliano
    Morandi, Matteo
    Rossetti, Barbara
    Tordini, Giacinta
    Cauda, Roberto
    De Luca, Andrea
    Di Giambenedetto, Simona
    Montagnani, Francesca
    PLOS ONE, 2016, 11 (06):
  • [9] Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy
    Lu, Ching-Lan
    Chang, Sui-Yuan
    Chuang, Yu-Chung
    Liu, Wen-Chun
    Su, Chin-Ting
    Su, Yi-Ching
    Chang, Shu-Fang
    Hung, Chien-Ching
    VACCINE, 2014, 32 (09) : 1031 - 1035
  • [10] Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine
    Glesby, Marshall J.
    Watson, Wendy
    Brinson, Cynthia
    Greenberg, Richard N.
    Lalezari, Jacob P.
    Skiest, Daniel
    Sundaraiyer, Vani
    Natuk, Robert
    Gurtman, Alejandra
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (01) : 18 - 27
12345